Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

← catalyst calendar

NCT06561048 · readout ≤ 468 d

Sponsored by Corvus Pharmaceuticals, Inc. (industry) · CRVS — their whole pipeline →.

Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
150estimated
Sites
34
Countries
Australia, Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-10-02actualWhen the study began enrolling
Primary completionNov 2027estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionDec 2028estimatedThe whole study's end, after follow-up
First posted2024-08-19actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-04-08actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Follicular T-Cell Lymphoma
  • Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
  • Systemic Anaplastic Large Cell Lymphoma
  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, T-Cell

Interventions

  • Drug: Soquelitinib — also filed as CPI-818
  • Drug: Belinostat — also filed as Beleodaq®
  • Drug: Pralatrexate — also filed as Folotyn®

Primary outcome

what the primary-completion date above is the date OF
Progression-free survival
measured Up to 4 years post study treatment initiation

Permalink · CRVS's whole pipeline · Catalyst calendar · Every registered study · What changed